Navigation Links
ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion)

tere induced an anaphylactoid type reaction consistent with hypersensitivity reactions, including acute increases in blood histamine levels and decreased blood pressure. In contrast, no hypersensitivity reactions, including no elevations in histamine levels and no changes in blood pressure were observed following dosing with ANX-514.

ADVENTRX is continuing to conduct additional preclinical pharmacokinetic testing of ANX-514 to compare this product candidate with the approved version of the product, marketed under the brand name Taxotere. The Company currently plans to seek guidance from the FDA with respect to the appropriateness of a Section 505(b)(2) NDA regulatory path for ANX-514, and pending agreement on clinical protocol design with the FDA, initiate a marketing-enabling clinical trial of ANX-514 in 2007.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, a product marketed under the brand name Taxotere. ANX-514 is designed to eliminate the need for multi-day immunosuppressant premedication. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of allergic reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers. In connection with a Section 505(b)(2) NDA covering ANX-514, ADVENTRX must certify that all applicable Taxotere patents have expired prior to the manufacture, use or sale of ANX-514.

About Section 505(b)(2)

Section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act (FDCA) allows the Food and Drug Administration (FDA) to approve a follow-on drug on the basis of data in
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:9/16/2014)... and BOSTON , September 16, ... Chief Scientific Officer, Fiona Marshall , will give a ... G protein-coupled receptors using StaR ®   ... Advances in Drug Discovery and Development " virtual symposium run ... Chemical Society. The virtual symposium is on Wednesday, 24 September ...
(Date:9/15/2014)... , Sept. 16, 2014  Bayer HealthCare ... Espoo, Finland , have begun ... with ODM-201, an investigational oral androgen receptor inhibitor ... ODM-201 in men with castration-resistant prostate cancer who ... no detectable metastases. The trial is designed to ...
(Date:9/15/2014)... 15, 2014 GenomeDx Biosciences today announced ... American Society for Radiation Oncology (ASTRO) Annual Meeting ... Classifier, a genomic test capable of predicting aggressiveness ... improve patient outcomes for prostate cancer patients following ... recently published study that demonstrates how Decipher test ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 2Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 3Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3
... SILVER SPRING, Md., July 1, 2011 The ... Neohaler (indacaterol inhalation powder) for the long term, ... people with chronic obstructive pulmonary disease (COPD) including ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) COPD is a ...
... DUBLIN, July 1, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that it ... District of New Jersey against each,of Amneal Pharmaceuticals, LLC ... Shire,s VYVANSE,patents. The lawsuits were initiated in ...
Cached Medicine Technology:FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease 2Shire Files Lawsuits Against Sandoz and Amneal for Infringement of VYVANSE® (lisdexamfetamine dimesylate) Patents 2
(Date:9/16/2014)... September 16, 2014 A recent ... used as a dermal filler, “Expression”, which has not ... on the market to be used as an intra-nasal ... FDA for use as a dermal filler. Because of ... off-label for wrinkle reduction, and patients have had bad ...
(Date:9/16/2014)... September 16, 2014 Dr. Eric Millstein ... of ACLsurgeryLA.com , a specialty website devoted to ... As an avid sports lover and athlete, Dr. Millstein ... and recovery from injuries to maintain active, healthy lifestyles. ... patients a resource dedicated specifically to ACL injuries ...
(Date:9/16/2014)... OXNARD, CA (PRWEB) September 16, 2014 ... Jivraj, founder of the Anacapa Dental Art Institute in ... Spectrum Day Vancouver conference this weekend. , Dr. Jivraj, ... about All-on-4™ dental implants in his presentation ... he will deliver at 12:40 p.m. Saturday, Sept. 20, ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Non-approved Dermal Filler 2Health News:FDA Warns Against Non-approved Dermal Filler 3Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2
... of,Public Welfare said today it is working with ... an abandoned child in,Lansdowne, Delaware County., An ... noon today and said, "I left a baby ... without providing any other information. Local law,enforcement was ...
... and large numbers of men, are interested in having cosmetic ... Journal of Plastic and Reconstructive Surgery. , ... in cosmetic surgery, liposuction or both, and another 23 percent ... Among men, 23 percent said they would be interested in ...
... /PRNewswire/ - The IND proposes a randomized Phase,III ... Best Supportive,Care (BSC) versus BSC alone for the ... gastroesophageal junction and stomach who,have failed adjuvant or ... of the IND and will direct the clinical ...
... Oct. 26 In a statewide,effort to help ... violence shelters, the Michigan State Medical Society (MSMS),Foundation ... and,distribute personal care items in conjunction with the ... Day" on,Saturday, October 27., "The women and ...
... WHEATON, Ill., Oct. 26 The following is a,media ... Rehabilitation Hospital is the 2007 recipient of the,James Brady ... or organization,that goes above and beyond to improve lives ... goals of the Brain Injury Association of,Illinois., In ...
... UniCare announced today a policy to,make it easy for ... the prescription drugs they need. A one-time override ... up so,that UniCare policyholders in the affected counties can ... in place for,members living in Los Angeles, Orange, San ...
Cached Medicine News:Health News:Safe Haven Hotline Receives Report of Abandoned Baby in Lansdowne 2Health News:Huge numbers willing to go under knife to alter their appearance, study finds 2Health News:Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract 2Health News:Michigan State Medical Society Foundation 'Makes A Difference' by Assisting Those in Crisis Shelters 2Health News:Marianjoy Rehabilitation Hospital to Receive James Brady Award From Brain Injury Association of Illinois 2Health News:UniCare Announces Temporary Pharmacy Guidelines for Customers Affected by the California Wildfires 2
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
... radial head system employs the advantages of ... create the next generation of modular radial ... modular design, the implant system offers the ... patients anatomy. In addition, the capability of ...
For connection to the bipolar output of electrosurgical generators....
Recommended for use with spark gap coagulators for added safety. Also available in stainless steel (10-3002)....
Medicine Products: